10-Q · June 4, 2026
MOBI reported a strong Q1 2026 performance with a 113.3% increase in revenue to $12.1 million compared to the same period last year, primarily driven by growing adoption of its Vivistim System. While gross margin…
Earnings analysis · 10-Q
MOBI earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Mobia Medical delivered strong Q2 top-line momentum, with revenue of $13.5 million, up 102% year over year, and gross margin of 83.2%. However, operating expenses rose 83% to $29.2 million, producing a $21.0 million net…
Read full summary
Mobia Medical delivered strong Q2 top-line momentum, with revenue of $13.5 million, up 102% year over year, and gross margin of 83.2%. However, operating expenses rose 83% to $29.2 million, producing a $21.0 million net loss and $(1.10) EPS, while the company also reported an ineffective control environment tied to EPS calculations. The $134.0 million of IPO net proceeds improves liquidity, but ongoing losses, elevated spending and the unremediated material weakness keep the overall sentiment neutral.
Reported figures
- Earnings per share
- $-1.1
- Gross margin
- 83.2%
What stood out
-
Revenue doubled and beat consensus
Q2 revenue was $13.5 million, up 102% year over year and $1.1 million above the $12.38 million consensus estimate.
-
Gross margin reached 83.2%
Gross margin expanded to 83.2% in Q2, indicating strong underlying product economics despite the quarterly loss.
-
IPO materially strengthened liquidity
The May 11, 2026 IPO generated approximately $134.0 million of net proceeds after $10.5 million of underwriting discounts and commissions and $5.5 million of offering expenses.
-
IPO proceeds remain largely liquid
Management stated that IPO proceeds were invested primarily in savings and money market accounts, with no material change to the expected use of proceeds described in the prospectus.
What to watch
-
Expense growth exceeds revenue growth
Operating expenses increased 83% to $29.2 million, substantially outpacing revenue growth and contributing to a net loss of $21.0 million and EPS of $(1.10).
-
Unremediated material weakness
Management concluded that disclosure controls and procedures were not effective as of June 30, 2026 because of a material weakness involving review of inputs used to calculate net loss per share.
-
Prior-period EPS reporting risk
The material weakness caused a revision to the weighted-average share count and net loss per share for the year ended December 31, 2025; management said it will not be considered remediated until the control operates effectively for a sufficient period.
Management's outlook
The supplied 10-Q text does not include quantitative guidance. The related earnings disclosure cites 2026 revenue guidance of $54.0 million to $56.0 million, but does not establish whether that outlook changed versus the prior outlook.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.